Match!
Endocrine-related Cancer
IF
4.77
Papers
2144
Papers 2173
1 page of 218 pages (2,173 results)
Newest
#1Chiara Ricci (UNIBO: University of Bologna)H-Index: 33
#2Stefano Partelli (UniSR: Vita-Salute San Raffaele University)H-Index: 29
Last. Massimo Falconi (UniSR: Vita-Salute San Raffaele University)H-Index: 79
view all 10 authors...
Overall survival (OS) is considered as the standard measure of outcome in oncology. However, considering that resectable pancreatic neuroendocrine neoplasms (Pan-NENs) usually have a long OS, the feasibility of prospective studies is questionable due to a long follow-up period needed. The primary endpoint was to validate the use of disease-free survival (DFS) as a surrogate measure of OS. The secondary endpoint was to calculate the gain in sample size using DFS instead of OS in hypothetical pros...
Source
#1Thi-Van-Trinh Tran (French Institute of Health and Medical Research)
#2Cari M. KitaharaH-Index: 23
Last. Neige Journy (French Institute of Health and Medical Research)H-Index: 2
view all 5 authors...
Source
#1Emanuel ChristH-Index: 31
#2Kwadwo AntwiH-Index: 5
Last. Damian WildH-Index: 26
view all 4 authors...
Source
#1Manisha Taya (URMC: University of Rochester Medical Center)H-Index: 3
#2Maria de la Luz Garcia-Hernandez (URMC: University of Rochester Medical Center)H-Index: 12
Last. Stephen R. Hammes (URMC: University of Rochester Medical Center)H-Index: 32
view all 6 authors...
Source
#1Hiroki Ide (Johns Hopkins University)H-Index: 16
#2Taichi Mizushima (URMC: University of Rochester Medical Center)H-Index: 6
Last. Alexander S. Baras (Johns Hopkins University)H-Index: 21
view all 13 authors...
Source
#1Isadora Pontes Cavalcante (University of Paris)
Last. Jérôme BertheratH-Index: 72
view all 11 authors...
Source
#1Xinyue Wang (SYSU: Sun Yat-sen University)H-Index: 1
#2Xiwen Bi (SYSU: Sun Yat-sen University)H-Index: 4
Last. Zhongyu Yuan (SYSU: Sun Yat-sen University)H-Index: 7
view all 7 authors...
Source
#1Woo Kyung LeeH-Index: 1
#2Won Gu KimH-Index: 28
Last. Sheue-yann ChengH-Index: 30
view all 9 authors...
Source
#1Tara Williamson (Johns Hopkins University)H-Index: 2
#2Thais Biude Mendes (UNIFESP: Federal University of São Paulo)H-Index: 1
Last. Gregory J. Riggins (Johns Hopkins University)H-Index: 55
view all 5 authors...
The most common thyroid malignancy is papillary thyroid cancer. While a majority respond to therapy and have a favorable prognosis, some papillary thyroid cancers persist. This subset may dedifferentiate to anaplastic thyroid cancer, an aggressive, highly invasive and rapidly fatal cancer. Thyroid cancer patients at risk for disease progression and metastasis need earlier, safer and more effective therapies. The purpose of this translational study was to determine if mebendazole could be repurpo...
Source
#1Halfdan Sorbye (Haukeland University Hospital)H-Index: 30
#2Grace Kong (Peter MacCallum Cancer Centre)H-Index: 12
Last. Simona Grozinsky-Glasberg (HUJI: Hebrew University of Jerusalem)H-Index: 20
view all 3 authors...
Peptide receptor radionuclide therapy (PRRT) is an established treatment for grade 1 and 2 gastroenteropancreatic neuroendocrine tumors with an increased uptake on somatostatin receptor imaging (SRI). Patients with metastatic high-grade (WHO G3) gastroenteropancreatic neuroendocrine neoplasms (NET G3 and NEC) represent a heterogeneous subgroup with poor prognosis and standard platinum-etoposide chemotherapy have limited therapeutic benefit. However, there is promising emerging evidence supportin...
Source
12345678910
Top fields of study
Cancer
Endocrinology
Cancer research
Breast cancer
Biology